Molecular Abnormalities in Schizophrenia: Neurotransmission, Oxidative Stress, and Apoptosis
Poster Jun 22, 2016
Elizabeth J. Want,1 Hendrik Wesseling, 2 Elaine Holmes, 1 and Sabine Bahn 2
Schizophrenia affects 1% of the world’s population.
• Broad, heterogeneous range of symptoms hinders the effectiveness of current therapies.
• New models reproducing core schizophrenia features are needed to elucidate pathological disease mechanisms, identify biomarkers for improved diagnosis and discover potential novel drug targets.
• A multi-platform approach was employed to analyse distinct brain regions implicated in schizophrenia.
We developed an automated sample preparation protocol based on a robotic platform PAL RTC (CTC Analytics AG, Zwingen Switzerland), which represent a modified Bligh and Dyer method producing samples for both hydrophilic metabolomics using GC-MS and lipidomics using SFC-MS simultaneously.READ MORE